{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T13:38:37Z","timestamp":1775741917831,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.urolonc.2021.07.009","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T11:45:24Z","timestamp":1627559124000},"page":"61.e9-61.e19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Oncological outcomes of concomitant carcinoma in situ at radical cystectomy in pure urothelial bladder cancer and in histological variants."],"prefix":"10.1016","volume":"40","author":[{"given":"Richard","family":"Naspro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"La Croce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Finati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Roscigno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Pellucchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Sodano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Manica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gianatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi F.","family":"Da Pozzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2021.07.009_bib0001","unstructured":"EAU Guidelines Office, Arnhem, The Netherlands. https:\/\/uroweb.org\/guideline\/bladder-cancer-muscle-invasive-and-metastatic\/accessed 2020"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0002","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ejso.2016.02.011","article-title":"Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: a 20-year single center experience","volume":"42","author":"Moschini","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0003","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2013.09.050","article-title":"Conditional survival after radical cystectomy for bladder cancer: evidence for a patient changing risk profile over time","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur Urol."},{"key":"10.1016\/j.urolonc.2021.07.009_bib0004","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","article-title":"Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients","volume":"61","author":"Hautmann","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0005","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0006","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"International collaboration of trialists; medical research council advanced bladder cancer working party (now the national cancer research institute bladder cancer clinical studies group); european organisation for research and treatment of cancer genito-urinary tract cancer group; australian bladder cancer study group; national cancer institute of canada clinical trials group; finnbladder; norwegian bladder cancer study group; club urologico espanol de tratamiento oncologico group","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0007","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0008","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/j.clgc.2016.07.014","article-title":"Validation of preoperative risk grouping of the selection of patients most likely to benefit from neoadjuvant chemotherapy before radical cystectomy","volume":"15","author":"Moschini","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0009","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2014.06.040","article-title":"Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with bacillus calmette-gu\u00e9rin: results of a retrospective multicenter study of 2451 patients","volume":"67","author":"Gontero","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0010","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/bju.12250","article-title":"Outcome in patients with exclusive carcinoma in situ (CIS) after radical cystectomy","volume":"113","author":"Zehnder","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0011","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1097\/01.ju.0000136294.15938.3d","article-title":"Outcomes in patients with pathological carcinoma in situ only disease at radical cystectomy","volume":"172","author":"Hassan","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0012","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1159\/000325463","article-title":"Concomitant carcinoma in situ in cystectomy specimens is not associated with clinical outcomes after surgery","volume":"87","author":"Nuhn","year":"2011","journal-title":"Urol Int"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0013","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s00345-013-1207-z","article-title":"Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer","volume":"32","author":"Yafi","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0014","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.eururo.2006.08.037","article-title":"Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy","volume":"51","author":"Shariat","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.urolonc.2015.09.001","article-title":"Effect on postoperative survival of the status of distal ureteral margin: the necessity to achieve negative margins at the time of radical cystectomy","volume":"34","author":"Moschini","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0016","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.urolonc.2016.11.003","article-title":"The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes","volume":"35","author":"Moschini","year":"2017","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0017","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.juro.2018.05.162","article-title":"Prognostic value of concomitant carcinoma in situ in the radical cystectomy specimen: a systematic review and meta-analysis","volume":"201","author":"Kimura","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0018","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00345-019-02738-2","article-title":"Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: a PRISMA-compliant systematic review and meta-analysis","volume":"38","author":"Zhang","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0019","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s00345-020-03364-z","article-title":"The impact of histological variants on outcomes after open radical cystectomy for muscle-invasive urothelial bladder cancer: results from a single tertiary referral centre","volume":"39(6)","author":"Naspro","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0020","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1002\/cncr.30907","article-title":"Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology","volume":"123","author":"Vetterlein","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0021","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.euf.2019.09.003","article-title":"What is the significance of variant histology in urothelial carcinoma?","volume":"6","author":"Lobo","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0022","first-page":"93","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \"personalized\" approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0023","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0024","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.eururo.2017.12.018","article-title":"Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers","volume":"73","author":"Paner","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0025","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1002\/ijc.24619","article-title":"Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of 2 major pathways in bladder cancer development","volume":"125","author":"Zieger","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0026","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.urolonc.2010.01.001","article-title":"Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ confined urothelial carcinoma following radical nephroureterectomy","volume":"30","author":"Wheat","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2021.07.009_bib0027","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00345-011-0645-8","article-title":"Concomitant carcinoma in situ as an independent prognostic parameter for recurrence and survival in upper tract urothelial carcinoma: a multicenter analysis of 772 patients","volume":"29","author":"Otto","year":"2011","journal-title":"World J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921003100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143921003100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:23:49Z","timestamp":1761042229000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143921003100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1078143921003100"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.009","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncological outcomes of concomitant carcinoma in situ at radical cystectomy in pure urothelial bladder cancer and in histological variants.","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2021.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}